Focused On-demand Library for SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily A-like protein 1

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

Our top-notch dedicated system is used to design specialised libraries for enzymes.

Fig. 1. The sreening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.

Our library stands out due to several important features:

The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

Q9NZC9

UPID:

SMAL1_HUMAN

Alternative names:

HepA-related protein; Sucrose nonfermenting protein 2-like 1

Alternative UPACC:

Q9NZC9; A6NEH0; Q53R00; Q96AY1; Q9NXQ5; Q9UFH3; Q9UI93

Background:

SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily A-like protein 1, also known as HepA-related protein and Sucrose nonfermenting protein 2-like 1, plays a crucial role in DNA repair and maintenance. It functions as an ATP-dependent annealing helicase, selectively binding to fork DNA over ssDNA or dsDNA, and catalyzes the rewinding of stably unwound DNA. This protein is essential across the genome for reannealing stably unwound DNA, counteracting the activity of enzymes that unwind DNA.

Therapeutic significance:

Schimke immuno-osseous dysplasia, a disorder linked to mutations in the gene encoding this protein, highlights its importance in human health. Understanding the role of SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily A-like protein 1 could open doors to potential therapeutic strategies for treating this pleiotropic disorder, which involves spondyloepiphyseal dysplasia, renal dysfunction, immunodeficiency, and arteriosclerosis.